$201.8 Million

MaxCyte, Inc.

Initial Public Offering

Lead Left Bookrunner, July 2021

MaxCyte, Inc.

MaxCyte, Inc. (“MaxCyte” or the “Company”) is a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. The Company’s proprietary Flow Electroporation platform, branded as ExPERT, facilitates the complex engineering of a wide variety of cells.